Analyst Consensus ?
ConsensusBuy18 ratings
Bullish1688.9%
Neutral211.1%
Bearish00.0%
Medline Inc. · MDLN · FY2026 Q2 · Calendar Q3 2026
Medline lifts sales outlook but cuts adjusted EBITDA guidance
Medline’s Q2 results show strong sales momentum and expanding customer and distribution opportunities, but the lower adjusted EBITDA outlook highlights a gap between growth and near-term profitability. The durability of earnings growth depends on managing inflation, quality remediation and retail softness while executing its investment plans.
Why did MDLN fall 12.8% after beating EPS estimates in FY2026 Q2?
Research this report with FN2. Free to start; review your question before sending.
Reported Before market openNASDAQHealthcare
$35.40B market cap
90quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.50
Consensus $0.35
EPS surprise
+41.9%
Reported versus consensus
Reported revenue
$7.68B
Consensus $7.52B
Revenue surprise
+2.2%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-12.8%
Event window
SPY move
-0.2%
Same window
Abnormal move
-12.6%
Stock minus SPY
Volume
4.7×
Versus trailing sessions
Subsequent drift
-1.0%
Up to 20 sessions
MDLNSPY benchmark
Ask FN2 about MDLN FY2026 Q2
Choose a question to continue your research
Why did MDLN fall 12.8% after beating EPS estimates in FY2026 Q2?What changed in MDLN's guidance and outlook in FY2026 Q2?Give me the bull and bear case for MDLN after FY2026 Q2 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management raised full-year organic sales guidance to 9–10% and lowered adjusted EBITDA guidance to $3.3–$3.4 billion. The call cited Middle East-related inflation, quality remediation and retail softness as pressures. Sales grew 12% year over year, with growth in both Medline Brand and Supply Chain Solutions. No prior-quarter analysis was supplied for comparison.
Guidance delta
Organic sales outlook increased to 9–10%; adjusted EBITDA outlook decreased to $3.3–$3.4 billion. Management attributed the EBITDA pressure to inflation, quality remediation and retail softness.
Key takeaways
- Q2 net sales increased 12% year over year; Medline Brand grew 7% and Supply Chain Solutions grew 16%.
- Management cited $650 million of new prime-vendor signings in the first half and further conversion opportunities.
- Distribution expansion and investment in automation, AI/IT and quality systems are central to the operating plan.
- Stronger sales guidance came alongside a lower adjusted EBITDA outlook, underscoring near-term margin pressure.
Management priorities
- Expand distribution capacity, including planned facilities in Southern California, Texas and the Midwest.
- Implement automation and AI in distribution facilities.
- Execute the FDA-related global quality action plan and reintroduce recalled products.
- Pursue Medline Brand conversions and realign retail sales efforts to regain market share.
Follow MDLN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$40.35Current
$37Low
$47.38Average
$60High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 5, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Outperform | Outperform | Maintain | Oct 22, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 9, 2026 |
| UBS | Buy | Buy | Maintain | Sep 25, 2026 |
| BTIG | Buy | Buy | Maintain | Aug 27, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 12, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 11, 2026 |
| Tigress Financial | Buy | Buy | Maintain | Aug 11, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 10, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 6, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 6, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 6, 2026 |
| Baird | Outperform | Outperform | Maintain | Jun 3, 2026 |
| BNP Paribas | Neutral | Neutral | Maintain | May 14, 2026 |
| Citigroup | Buy | Buy | Maintain | May 7, 2026 |
| Bernstein | Outperform | Outperform | Maintain | May 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 2, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Feb 26, 2026 |
Named analyst price targets
Upside is calculated against the persisted current price $40.35. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Steven Valiquette | $45 | $35.31 | +11.5% | Oct 22, 2026 |
| Barclays | Analyst unavailable | $43 | $35.74 | +6.6% | Oct 9, 2026 |
| UBS | Kevin Caliendo | $43 | $34.8 | +6.6% | Sep 25, 2026 |
| BTIG | David Larsen | $55 | $34.58 | +36.3% | Aug 27, 2026 |
| Robert W. Baird | Eric Coldwell | $42 | $35.3 | +4.1% | Aug 6, 2026 |
| Evercore ISI | Analyst unavailable | $39 | $35.71 | -3.3% | Aug 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $45 | $35.54 | +11.5% | Aug 6, 2026 |
| BMO Capital | Sean Dodge | $47 | $36.66 | +16.5% | Aug 6, 2026 |
| RBC Capital | Analyst unavailable | $46 | $36.66 | +14.0% | Aug 6, 2026 |
| Deutsche Bank | Analyst unavailable | $37 | $36.66 | -8.3% | Aug 6, 2026 |
| Robert W. Baird | Eric Coldwell | $45 | $33.19 | +11.5% | Jun 3, 2026 |
| Barclays | Glen Santangelo | $45 | $36.56 | +11.5% | Jun 1, 2026 |
| Deutsche Bank | Analyst unavailable | $42 | $41.95 | +4.1% | May 7, 2026 |
| Tigress Financial | Ivan Feinseth | $60 | $43.41 | +48.7% | Mar 9, 2026 |
| Leerink Partners | Michael Cherny | $56 | $48.18 | +38.8% | Feb 25, 2026 |
| Stifel Nicolaus | Analyst unavailable | $55 | $48.18 | +36.3% | Feb 25, 2026 |
| Evercore ISI | Analyst unavailable | $55 | $49.38 | +36.3% | Feb 25, 2026 |
| Tigress Financial | Analyst unavailable | $55 | $45.01 | +36.3% | Feb 5, 2026 |
| J.P. Morgan | David Larsen | $55 | $43.16 | +36.3% | Jan 21, 2026 |
| Barclays | Analyst unavailable | $50 | $41.65 | +23.9% | Jan 12, 2026 |
| BNP Paribas | Analyst unavailable | $38 | $42.18 | -5.8% | Jan 12, 2026 |
| Wolfe Research | Analyst unavailable | $47 | $41.88 | +16.5% | Jan 12, 2026 |
| Deutsche Bank | Analyst unavailable | $40 | $40.52 | -0.9% | Jan 12, 2026 |
| Wells Fargo | Analyst unavailable | $42 | $40.52 | +4.1% | Jan 12, 2026 |
| BTIG | Analyst unavailable | $50 | $40.52 | +23.9% | Jan 12, 2026 |
| Mizuho Securities | Analyst unavailable | $48 | $40.52 | +19.0% | Jan 12, 2026 |
| UBS | Analyst unavailable | $48 | $40.52 | +19.0% | Jan 12, 2026 |
| Stifel Nicolaus | Analyst unavailable | $46 | $40.52 | +14.0% | Jan 12, 2026 |
| Redburn Partners | Ed Ridley-Day | $42 | $40.52 | +4.1% | Jan 12, 2026 |
| Leerink Partners | Analyst unavailable | $48 | $40.52 | +19.0% | Jan 12, 2026 |
| Evercore ISI | Elizabeth Anderson | $50 | $40.52 | +23.9% | Jan 12, 2026 |
| Bernstein | Analyst unavailable | $49 | $40.52 | +21.4% | Jan 12, 2026 |
| Truist Financial | Analyst unavailable | $52 | $40.52 | +28.9% | Jan 12, 2026 |
| Piper Sandler | Jason Bednar | $50 | $40.52 | +23.9% | Jan 12, 2026 |
| Robert W. Baird | Eric Coldwell | $48 | $40.52 | +19.0% | Jan 12, 2026 |
| BMO Capital | Sean Dodge | $45 | $40.52 | +11.5% | Jan 12, 2026 |
| Goldman Sachs | David Roman | $49 | $40.52 | +21.4% | Jan 12, 2026 |
| RBC Capital | Analyst unavailable | $47 | $40.52 | +16.5% | Jan 12, 2026 |
| Morgan Stanley | Patrick Wood | $48 | $40.52 | +19.0% | Jan 11, 2026 |
Track every rating change on MDLN the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMedline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings.…
Historical context
All MDLN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| UTHR United Therapeutics Corporation | FY2026 Q3 · Calendar Q4 2026 | -5.0% | +1.2% | United Therapeutics posts record Q3 revenue as Tyvaso leads; inhaler filing slips to 2027 |
| CVS CVS Health Corp. | FY2026 Q3 · Calendar Q4 2026 | — | -12.5% | CVS raises 2026 outlook and plans a two-company separation |
| COR Cencora, Inc. | FY2026 Q4 · Calendar Q4 2026 | — | +4.0% | Cencora leans on specialty growth as FY2027 expansion requires investment |
| PODD Insulet Corp. | FY2026 Q3 · Calendar Q4 2026 | — | +6.6% | Insulet raises 2026 growth outlook as customer base and international sales expand |
| RPRX Royalty Pharma plc | FY2026 Q3 · Calendar Q4 2026 | — | +1.4% | Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand |
| ZBH Zimmer Biomet Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +14.6% | Zimmer Biomet raises 2026 outlook as hip and technology growth offset knee weakness |
Latest beats and misses
Who reports nextBeat on EPS
- QFY2026 Q3 · November 4, 2026+21.7% EPS-0.1% move
- MCDFY2026 Q3 · November 4, 2026+5.6% EPS+6.5% move
- SNFY2026 Q3 · November 4, 2026+23.2% EPS+4.1% move
- SWKFY2026 Q3 · November 4, 2026+49.0% EPS+13.1% move
- SKMFY2026 Q3 · November 4, 2026+4.0% EPS+2.5% move
- UNMAFY2026 Q3 · November 3, 2026+1.9% EPS+0.5% move
Missed on EPS
- UTHRFY2026 Q3 · November 4, 2026-5.0% EPS+1.2% move
- TRMBFY2026 Q3 · November 4, 2026-0.2% EPS-17.3% move
- OCFY2026 Q3 · November 4, 2026-20.5% EPS+8.5% move
- OHIFY2026 Q3 · November 3, 2026-42.5% EPS+3.5% move
- MOSFY2026 Q3 · November 3, 2026-1656.0% EPS+17.4% move
- OVVFY2026 Q3 · November 3, 2026-2.0% EPS-5.1% move
Get the MDLN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-05T20:12:12.915559+00:00
- FN2 earnings calendar · 2026-09-10T01:23:13.706414+00:00
- Polygon adjusted daily market bars · 2026-11-05T04:10:43.992668+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-05T04:10:43.989965+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-05. For educational purposes only; not investment advice.